Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Journal of Neurology
Erschienen in: Journal of Neurology 6/2019

27.11.2018 | Neurological Update

Update on opsoclonus–myoclonus syndrome in adults

verfasst von: Sun-Young Oh, Ji-Soo Kim, Marianne Dieterich

Erschienen in: Journal of Neurology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Opsoclonus–myoclonus syndrome in adults is a rare and heterogeneous disorder with the clinical features of opsoclonus, myoclonus, ataxia, and behavioral and sleep disturbances. The pathophysiology is thought to be immunological on the basis of paraneoplastic or infectious etiologies. Immunomodulatory therapies should be performed although the response may be incomplete. A number of autoantibodies have been identified against a variety of antigens, but no diagnostic immunological marker has yet been identified. This review focuses on underlying mechanisms of opsoclonus–myoclonus syndrome, including findings that have been identified recently, and provides an update on the clinical features and treatments of this condition.
Literatur
1.
2.
Pang KK, de Sousa C, Lang B, Pike MG (2010) A prospective study of the presentation and management of dancing eye syndrome/opsoclonus–myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 14:156–161CrossRefPubMed
3.
Rothenberg AB, Berdon WE, D’Angio GJ, Yamashiro DJ, Cowles RA (2009) The association between neuroblastoma and opsoclonus–myoclonus syndrome: a historical review. Pediatr Radiol 39:723–726CrossRefPubMed
4.
Luque FA, Furneaux HM, Ferziger R et al (1991) Anti-Ri—an antibody associated with paraneoplastic opsoclonus and breast-cancer. Ann Neurol 29:241–251CrossRefPubMed
5.
Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NKV, Dalmau J (2003) Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann Neurol 53:347–353CrossRefPubMed
6.
Armangue T, Sabater L, Torres-Vega E et al (2016) Clinical and immunological features of opsoclonus–myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 73:417–424CrossRefPubMedPubMedCentral
7.
Herman TE, Siegel MJ (2009) Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 48:336–340CrossRef
8.
Krug P, Schleiermacher G, Michon J et al (2010) Opsoclonus–myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 14:400–409CrossRefPubMed
9.
Digre KB (1986) Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 43:1165–1175CrossRefPubMed
10.
Whiteley AM, Swash M, Urich H (1976) Progressive encephalomyelitis with rigidity. Brain 99:27–42CrossRefPubMed
11.
McKeon A, Pittock SJ, Glass GA et al (2007) Whole-body tremulousness: isolated generalized polymyoclonus. Arch Neurol 64:1318–1322CrossRefPubMed
12.
Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ (2005) Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus–myoclonus syndrome. J Pediatr Oncol Nurs 22:8–19CrossRefPubMed
13.
De Grandis E, Parodi S, Conte M et al (2009) Long-term follow-up of neuroblastoma-associated opsoclonus–myoclonus-ataxia syndrome. Neuropediatrics 40:103–111CrossRefPubMed
14.
Matthay KK, Blaes F, Hero B et al (2005) Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 228:275–282CrossRef
15.
Pranzatelli MR (1996) The immunopharmacology of the opsoclonus–myoclonus syndrome. Clin Neuropharmacol 19:1–47CrossRefPubMed
16.
Anderson NE, Buddesteffen C, Rosenblum MK et al (1988) Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer—a distinct para-neoplastic syndrome. Medicine 67:100–109CrossRefPubMed
17.
Antunes NL, Khakoo Y, Matthay KK et al (2000) Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus–myoclonus. J Pediatr Hematol Oncol 22:315–320CrossRefPubMed
18.
Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937CrossRefPubMed
19.
Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J (2001) Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50:339–348CrossRefPubMed
20.
Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA (2001) Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189:71–81CrossRefPubMed
21.
Kurian M, Lalive PH, Dalmau JO, Horvath J (2010) Opsoclonus–myoclonus syndrome in anti-N-methyl-d-aspartate receptor encephalitis. Arch Neurol 67:118–121CrossRefPubMedPubMedCentral
22.
Saiz A, Dalmau J, Butler MH et al (1999) Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 66:214–217CrossRefPubMedPubMedCentral
23.
Bataller L, Graus F, Saiz A, Vilchez JJ, Spanish Opsoclonus–myoclonus Study G (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124:437–443CrossRefPubMed
24.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154CrossRefPubMed
25.
Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J (2003) Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann Neurol 53:347–353CrossRefPubMed
26.
Noetzel MJ, Cawley LP, James VL, Minard BJ, Agrawal HC (1987) Anti-neurofilament protein antibodies in opsoclonus–myoclonus. J Neuroimmunol 15:137–145CrossRefPubMed
27.
Dropcho EJ, Kline LB, Riser J (1993) Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus–myoclonus. Neurology 43:207–211CrossRefPubMed
28.
Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53:580–587CrossRefPubMed
29.
Bataller L, Graus F, Saiz A, Vilchez JJ, Study SOM (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124:437–443CrossRefPubMed
30.
Scholz J, Vieregge P, Ruff C (1994) Paraneoplastic opsoclonus–myoclonus syndrome in metastatic ovarian-carcinoma. J Neurol Neurosur Ps 57:763–764CrossRef
31.
Caviness JN, Forsyth PA, Layton DD, Mcphee TJ (1995) The movement disorder of adult opsoclonus. Mov Disord 10:22–27CrossRefPubMed
32.
Jongen JLM, Moll WJB, Smitt PAES, Vecht CJ, Tijssen CC (1998) Anti-Ri positive opsoclonus–myoclonus-ataxia in ovarian duct cancer. J Neurol 245:691–692CrossRefPubMed
33.
Moretti R, Torre P, Antonello RM, Nasuelli D, Cazzato G (2000) Opsoclonus–myoclonus syndrome: gabapentin as a new therapeutic proposal. Eur J Neurol 7:455–456CrossRefPubMed
34.
Lou E, Hensley ML, Lassman AB, Aghajanian C (2010) Paraneoplastic opsoclonus–myoclonus syndrome secondary to immature ovarian teratoma. Gynecol Oncol 117:382–384CrossRefPubMed
35.
De Luca S, Terrone C, Crivellaro S et al (2002) Opsoclonus–myoclonus syndrome as a paraneoplastic manifestation of renal cell carcinoma—a case report and review of the literature. Urol Int 68:206–208CrossRefPubMed
36.
Kumar A, Lajara-Nanson WA, Neilson RW (2005) Paraneoplastic opsoclonus–myoclonus syndrome: initial presentation of non-Hodgkins lymphoma. J Neuro Oncol 73:43–45CrossRef
37.
Berger JR, Mehari E (1999) Paraneoplastic opsoclonus–myoclonus secondary to malignant melanoma. J Neuro Oncol 41:43–45CrossRef
38.
Jung KY, Youn J, Chung CS (2006) Opsoclonus–myoclonus syndrome in an adult with malignant melanoma. J Neurol 253:942–943CrossRefPubMed
39.
Blaes F, Pike MG, Lang B (2008) Autoantibodies in childhood opsoclonus–myoclonus syndrome. J Neuroimmunol 201:221–226CrossRefPubMed
40.
Klaas JP, Ahlskog JE, Pittock SJ et al (2012) Adult-onset opsoclonus–myoclonus syndrome. Arch Neurol 69:1598–1607CrossRefPubMed
41.
Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY (1994) Paraneoplastic opsoclonus–myoclonus associated with anti-Hu antibody. Neurology 44:1754–1755CrossRefPubMed
42.
Smith JH, Dhamija R, Moseley BD et al (2011) N-Methyl-d-aspartate receptor autoimmune encephalitis presenting with opsoclonus–myoclonus treatment response to plasmapheresis. Arch Neurol-Chicago 68:1069–1072CrossRefPubMed
43.
Josephson CB, Grant I, Benstead T (2009) Opsoclonus–myoclonus with multiple paraneoplastic syndromes and VGCC antibodies. Can J Neurol Sci 36:512–514CrossRefPubMed
44.
Simister RJ, Ng K, Lang B, Beckles M, Chao D, McCabe DJH (2011) Sequential fluctuating paraneoplastic ocular flutter-opsoclonus–myoclonus syndrome and Lambert-Eaton myasthenic syndrome in small-cell lung cancer. J Neurol Neurosur Ps 82:344–346CrossRef
45.
Dalakas MC (2008) Invited article: inhibition of B cell functions—implications for neurology. Neurology 70:2252–2260CrossRefPubMed
46.
Pranzatelli MR, Travelstead AL, Tate ED et al (2004) B- and T-cell markers in opsoclonus–myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 62:1526–1532CrossRefPubMed
47.
Pranzatelli MR, Tate ED, McGee NR et al (2013) BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflamm 10:10CrossRef
48.
Raffaghello L, Conte M, De Grandis E, Pistoia V (2009) Immunological mechanisms in opsoclonus–myoclonus associated neuroblastoma. EJPN 13:219–223CrossRefPubMed
49.
Fuhlhuber V, Altenkamper S, Bick S et al (2008) Serum and cerebrospinal fluid levels of the B-cell activating factor BAFF in paediatric opsoclonus–myoclonus syndrome—correlation with neuronal surface-binding autoantibodies. J Neurol 255:54–54
50.
Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA (2008) Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus–myoclonus syndrome. Cytokine 44:26–32CrossRefPubMed
51.
52.
Scott KM, Parker F, Heckmann JM (2009) Opsoclonus–myoclonus syndrome and HIV-infection. J Neurol Sci 284:192–195CrossRefPubMed
53.
Huber BM, Strozzi S, Steinlin M, Aebi C, Fluri S (2010) Mycoplasma pneumoniae associated opsoclonus–myoclonus syndrome in three cases. Eur J Pediatr 169:441–445CrossRefPubMed
54.
Flabeau O, Meissner W, Foubert-Samier A, Guehl D, Desbordes P, Tison F (2009) Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 24:2306–2308CrossRefPubMed
55.
Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M (2007) Opsoclonus–myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 68:1636CrossRefPubMed
56.
Crawford JR, Kadom N, Santi MR, Mariani B, Lavenstein BL (2007) Human herpesvirus 6 rhombencephalitis in immunocompetent children. J Child Neurol 22:1260–1268CrossRefPubMed
57.
Ertekin V, Tan H (2010) Opsoclonus–myoclonus Syndrome Attributable to Hepatitis C Infection. Pediatr Neurol 42:441–442CrossRefPubMed
58.
Ayarza A, Parisi V, Altclas J et al (2009) Opsoclonus–myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 256:1024–1025CrossRefPubMed
59.
Kanjanasut N, Phanthumchinda K, Bhidayasiri R (2010) HIV-related opsoclonus–myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg 112:572–574CrossRefPubMed
60.
61.
Verma A, Brozman B (2002) Opsoclonus–myoclonus syndrome following Epstein-Barr virus infection. Neurology 58:1131–1132CrossRefPubMed
62.
Khosla JS, Edelman MJ, Kennedy N, Reich SG (2005) West Nile virus presenting as opsoclonus–myoclonus cerebellar ataxia. Neurology 64:1095–1095CrossRefPubMed
63.
Krasenbrink I, Fuhlhuber V, Juhasz-Boess I et al (2007) Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus–myoclonus syndrome (OMS). Neuropediatrics 38:114–116CrossRefPubMed
64.
Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A (2008) Opsoclonus–myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg 110:619–621CrossRefPubMed
65.
66.
Koide R, Sakamoto M, Tanaka K, Hayashi H (2004) Opsoclonus–myoclonus syndrome during pregnancy. J Neuro-Ophthalmol 24:273–273CrossRef
67.
Zee DS, Robinson DA (1979) A hypothetical explanation of saccadic oscillations. Ann Neurol 5:405–414CrossRefPubMed
68.
Ridley A, Kennard C, Scholtz CL, Buttner-Ennever JA, Summers B, Turnbull A (1987) Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110(Pt 6):1699–1709CrossRefPubMed
69.
70.
Bhidayasiri R, Somers JT, Kim JI et al (2001) Ocular oscillations induced by shifts of the direction and depth of visual fixation. Ann Neurol 49:24–28CrossRefPubMed
71.
Shaikh AG, Ramat S, Optican LM, Miura K, Leigh RJ, Zee DS (2008) Saccadic burst cell membrane dysfunction is responsible for saccadic oscillations. J Neuroophthalmol 28:329–336CrossRefPubMedPubMedCentral
72.
Ramat S, Leigh RJ, Zee DS, Optican LM (2005) Ocular oscillations generated by coupling of brainstem excitatory and inhibitory saccadic burst neurons. Exp Brain Res 160:89–106CrossRefPubMed
73.
Ramat S, Leigh RJ, Zee DS, Optican LM (2007) What clinical disorders tell us about the neural control of saccadic eye movements. Brain 130:10–35CrossRefPubMed
74.
Helmchen C, Rambold H, Sprenger A, Erdmann C, Binkofski F (2003) f MRIs. Cerebellar activation in opsoclonus: an fMRI study. Neurology 61:412–415CrossRefPubMed
75.
van Toorn R, Rabie H, Warwick JM (2005) Opsoclonus–myoclonus in an HIV-infected child on antiretroviral therapy-possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 9:423–426CrossRefPubMed
76.
Blumkin L, Kivity S, Lev D et al (2012) A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus–myoclonus ataxia-like syndrome. J Neurol 259:2590–2598CrossRefPubMed
77.
Oh SY, Boegle R, Eulenburg PZ, Ertl M, Kim JS, Dieterich M (2017) Longitudinal multi-modal neuroimaging in opsoclonus–myoclonus syndrome. J Neurol 264:512–519CrossRefPubMed
78.
Sperry RW (1950) Neural basis of the spontaneous optokinetic response produced by visual inversion. J Comp Physiol Psychol 43:482–489CrossRef
79.
Paus T, Marrett S, Worsley KJ, Evans AC (1995) Extraretinal modulation of cerebral blood flow in the human visual cortex: implications for saccadic suppression. J Neurophysiol 74:2179–2183CrossRefPubMed
80.
Burr DC, Morrone MC, Ross J (1994) Selective suppression of the magnocellular visual pathway during saccadic eye movements. Nature 371:511–513CrossRefPubMed
81.
Blaes F, Fuhlhuber V, Korfei M et al (2005) Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 58:313–317CrossRefPubMed
82.
Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593CrossRef
83.
Pranzatelli MR, Tate ED, Shenoy S, Travelstead AL (2012) Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus–myoclonus. Pediatr Blood Cancer 58:988–991CrossRefPubMed
84.
Rudnick E, Khakoo Y, Antunes NL et al (2001) Opsoclonus–myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. Med Pediatr Oncol 36:612–622CrossRefPubMed
85.
Mitchell WG, Davalos-Gonzalez Y, Brumm VL et al (2002) Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 109:86–98CrossRef
86.
Hammer MS, Larsen MB, Stack CV (1995) Outcome of children with opsoclonus–myoclonus regardless of etiology. Pediatr Neurol 13:21–24CrossRefPubMed
87.
Rostasy K, Wilken B, Baumann M et al (2006) High dose pulsatile dexamethasone therapy in children with opsoclonus–myoclonus syndrome. Neuropediatrics 37:291–295CrossRefPubMed
88.
Ertle F, Behnisch W, Al Mulla NA et al (2008) Treatment of neuroblastoma-related opsoclonus–myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 50:683–687CrossRefPubMed
89.
Gorman MP (2010) Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus-ataxia syndrome. Curr Opin Pediatr 22:745–750CrossRefPubMed
90.
de Alarcon PA, Matthay KK, London WB et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc 2:25–34CrossRef
91.
Wilken B, Baumann M, Bien CG, Hero B, Rostasy K, Hanefeld F (2008) Chronic relapsing opsoclonus–myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 12:51–55CrossRefPubMed
92.
Pranzatelli MR, Tate ED, Galvan I, Wheeler A (2001) Controlled pilot study of piracetam for pediatric opsoclonus–myoclonus. Clin Neuropharmacol 24:352–357CrossRefPubMed
93.
Mitchell WG, Wooten AA, O’Neil SH, Rodriguez JG, Cruz RE, Wittern R (2015) Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol 30:976–982CrossRefPubMed
94.
Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen MLC, van Noesel MM, Hakvoort-Cammel FGAJ, van den Heuvel-Eibrink MM (2009) Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 53:1048–1053CrossRefPubMed
Metadaten
Titel
Update on opsoclonus–myoclonus syndrome in adults
verfasst von
Sun-Young Oh
Ji-Soo Kim
Marianne Dieterich
Publikationsdatum
27.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-9138-7

Weitere Artikel der Ausgabe 6/2019

Journal of Neurology 6/2019 Zur Ausgabe

Review

Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment

Correction

Correction to: A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features

Original Communication

Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease

Retraction Note

Retraction Note to: Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms

Journal Club

What is the role of the cerebellum in the pathophysiology of dystonia?

Letter to the Editors

Chronic headache with vasospasm treated with nimodipine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise